Future Medicine such as Gene or Stem Cell Therapy Are Better Than Non biological or Some Biological (Antibiotic)
International Journal of Genetics and Genomics
Volume 4, Issue 6, December 2016, Pages: 51-54
Received: Sep. 17, 2016; Accepted: Oct. 19, 2016; Published: Jan. 25, 2017
Views 2198      Downloads 85
Author
Ikram Hasan, Department of Pharmacy, Bgc Trust University Bangladesh, Chittagong, Bangladesh
Article Tools
Follow on us
Abstract
At present all the drug both some biological (only antibiotic or antimicrobial agent) and Non biological drug gradually decrease their efficacy. Biological drugs such as antimicrobial agents, antibiotics are gradually resistance by microorganism. After 20 to 40 years later 60 to 90 percent antibiotics or antimicrobial agents will be resistance by microorganism. Non biological drug could not bind properly with their specific receptor due to structural change of receptor or decrease the affinity of drug to receptor. After 30 to 40 years later the drug efficacy will be gradually decrease at low level and show low therapeutic effect.At this time the innovative treatment such as gene therapy, stem cell therapy are the more dependable treatment for control or prevent or cure of the diseases. Specific gene therapy used for specific disease control or cure. Manipulation of gene in the human cell and produce protective agent (such as protein, antibody, enzyme) which inhibit the growth or kill of the microorganism and also control the hormonal diseases and cellular function and this protective agent such as protein which bind with receptor (structural change receptor which could not bind with Non biological drug) and give the desire function.On the other hand, stem cell therapy which control the all abnormal cell such as cancer cell, hormonal disfunction cell etc and prevent the diseases and give the desires cellular function.
Keywords
Non biological Drug, Antibiotic, Gene Therapy, Stem Cell Therapy
To cite this article
Ikram Hasan, Future Medicine such as Gene or Stem Cell Therapy Are Better Than Non biological or Some Biological (Antibiotic), International Journal of Genetics and Genomics. Vol. 4, No. 6, 2016, pp. 51-54. doi: 10.11648/j.ijgg.20160406.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Friedmann T; Roblin R (1972). “Gene Therapy for Human Genetic Disease?”. Science.175 (4025): 949–955. Bibcode:1972Sci...175..949F.doi:10.1126/science.175.4025.949. PMID 5061866.
[2]
“Human Cloning and Genetic Modification”. Association of Reproductive Health Officials. 2013. Archived from the original on 18 June 2013.
[3]
Gurtner GC, Callaghan MJ, Longaker MT (2007). “Progress and potential for regenerative medicine”. Annu. Rev. Med. 58 (1): 299–312. doi:10.1146/annurev.med.58.082405.095329. PMID 17076602.
[4]
Ptaszek LM, Mansour M, Ruskin JN, Chien KR (2012). “Towards regenerative therapy for cardiac disease”. The Lancet. 379 (9819): 933–942. doi:10.1016/s0140-6736(12)60075-0.
[5]
Malliaras K.; Kreke M.; Marban E. (2011). “The stuttering progress of cell therapy for heart disease”. Clinical pharmacology and therapeutics. 90 (4): 532–541. doi:10.1038/clpt.2011.175. PMID 21900888.
[6]
6. Giarratana MC, Kobari L, Lapillonne H, et al. (January 2005). “Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells”. Nat. Biotechnol. 23 (1): 69–74. doi:10.1038/nbt1047. PMID 15619619.
[7]
Yousef, M; Schannwell, CM; Köstering, M; Zeus, T; Brehm, M; Strauer, BE (16 June 2009). “The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction”. Journal of the American College of Cardiology. 53 (24): 2262–9. doi:10.1016/j.jacc.2009.02.051. PMID 19520249.
[8]
Schellekens H., Klinger E., Mühlebach S., Brin J., Storm G., Crommelin D. J. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 59, 176–183 (2011).
[9]
Mühlebach S., Vulto A., de Vlieger J. S. B., Weinstein V., Flühmann B., Shah V. P. The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead? GaBI J. 2(4), 1–4 (2013).
[10]
Crommelin, D. J., & de Vlieger, J. S. (2015). Epilogue: What Did We Learn? What Can We Expect in the Future? Concluding Remarks and Outstanding Issues. In Non-Biological Complex Drugs (pp. 381-388). Springer International Publishing.
[11]
Andersson D, Hughes D (2011). “Persistence of antibiotic resistance in bacterial populations”. FEMS Microbiol Rev. 35: 901–911. doi:10.1111/j.1574-6976.2011.00289.x.
[12]
“Annual Report of the Chief Medical Officer - Infections and the rise of antimicrobial resistance” (PDF). UK NHS. 2011. Archived from the original (PDF) on 22 June 2013.
[13]
Cavazzana-Calvo, M.; Thrasher, A.; Mavilio, F. (2004). “The future of gene therapy”. Nature. 427 (6977): 779–781. Bibcode: 2004 Natur.427. 779C. doi:10.1038/427779a.PMID 14985734.
[14]
Levy, Stuart B. (2002-01-01). “Factors impacting on the problem of antibiotic resistance”. Journal of Antimicrobial Chemotherapy. 49 (1): 25–30. doi:10.1093/jac/49.1.25. ISSN 0305-7453. PMID 11751763.
[15]
Borchard, G., Flühmann, B., & Mühlebach, S. (2012). Nanoparticle iron medicinal products–Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regulatory Toxicology and Pharmacology, 64(2), 324-328.
[16]
Schellekens H., Klinger E., Mühlebach S., Brin J., Storm G., Crommelin D. J. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 59, 176–183 (2011).
[17]
Biggest Threats - Antibiotic/Antimicrobial Resistance - CDC”. www.cdc.gov. Retrieved 2016-05-05.
[18]
Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R (January 2008). “Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis”. J. Antimicrob. Chemother. 61 (1): 26–38. doi:10.1093/jac/dkm416. PMID 17986491. (subscription required).
[19]
Herper, Matthew (26 March 2014) Gene Therapy's Big Comeback Forbes. Retrieved 28 April 2014.
[20]
Gene Therapy Clinical Trials Worldwide Database. The Journal of Gene Medicine. Wiley (June 2016).
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186